Key facts
- This page summarizes David Y. Liu's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
- 10 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 17 Nov 2022, 17:24.
David Y. Liu - 16 Nov 2022 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)
- Reporting relationship
- Chief R&D Strategy Officer
- Issuer ticker
- PTGX
- Reported as of
- 16 Nov 2022
- Net transaction value
- +$231,802
- SEC form
- 4
- Accepted by SEC
- 17 Nov 2022, 17:24:16 UTC
- Prior SEC filing
- 02 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Asif Ali, Attorney-in-Fact for David Y. Liu
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Y. Liu filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 17 Nov 2022.
Change
- Previous filing in this sequence was filed on 02 Mar 2022.
- Current net transaction value: +$231,802.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- $11,977
- Shares
- +13,767
- Change %
- +21%
- Price
- $0.8700*
- Shares after
- 80,878
- Date
- 16 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- $18,382
- Shares
- +9,726
- Change %
- +12%
- Price
- $1.89*
- Shares after
- 90,604
- Date
- 16 Nov 2022
- Ownership
- Direct
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- $11,338
- Shares
- +5,999
- Change %
- +6.6%
- Price
- $1.89*
- Shares after
- 96,603
- Date
- 16 Nov 2022
- Ownership
- Direct
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- $41,361
- Shares
- +35,656
- Change %
- +37%
- Price
- $1.16*
- Shares after
- 132,259
- Date
- 16 Nov 2022
- Ownership
- Direct
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- $148,744
- Shares
- +35,331
- Change %
- +27%
- Price
- $4.21
- Shares after
- 167,590
- Date
- 16 Nov 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -13,767
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,767
- Exercise price
- $0.8700
- Footnotes
- F2
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -9,726
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,726
- Exercise price
- $1.89
- Footnotes
- F2
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,999
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,999
- Exercise price
- $1.89
- Footnotes
- F2
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -35,656
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,656
- Exercise price
- $1.16
- Footnotes
- F2
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -35,331
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,331
- Exercise price
- $4.21
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022.
Footnote F2
The stock option is vested in full.
SEC remarks
Exhibit 24 - Power of Attorney